07 February 2013 08:59 [Source: ICIS news]
SINGAPORE (ICIS)--French pharmaceutical firm Sanofi reported on Thursday a 71.5% year-on-year plunge in its fourth-quarter net income to €410m ($554m), with sales barely increasing.
Its net sales for the December quarter inched up by 0.2% to €8.53bn, largely because of patent expirations, Sanofi said in a statement.
For the whole of 2012, Sanofi’s net profit declined by 12.8% to €4.97bn, despite a 4.7% increase in sales to €34.9bn, it said.
“2012 was a turning point for Sanofi with the loss of exclusivity in the US for several significant legacy drugs,” said Sanofi CEO Christopher Viehbacher in the statement.
This year, the first-half performance is expected to see a residual effect from the patent expirations, but the company should be able to resume growth in the second half, Viehbacher said.
($1 = €0.74)
For the latest chemical news, data and analysis that directly impacts your business sign up for a free trial to ICIS news - the breaking online news service for the global chemical industry.
Get the facts and analysis behind the headlines from our market leading weekly magazine: sign up to a free trial to ICIS Chemical Business.
|ICIS news FREE TRIAL|
|Get access to breaking chemical news as it happens.|
|ICIS Global Petrochemical Index (IPEX)|
|ICIS Global Petrochemical Index (IPEX). Download the free tabular data and a chart of the historical index|
Asian Chemical Connections